Alumis Advances Envudeucitinib With 54% PASI 100 Response
SOUTH SAN FRANCISCO, California, August 10, 2026 Alumis Inc. announced topline long-term results from the ongoing Phase 3 ONWARD3...
TYK2 inhibitor
Advertisement
InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint
Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...
Takeda Reports Strong Phase 3 Zasocitinib Results
Osaka, Japan & Cambridge, Mass., July 16, 2026 Takeda announced new Phase 3 data demonstrating that its investigational oral...
InnoCare Reports Positive Phase II Soficitinib Results
Beijing, July 16, 2026 InnoCare Pharma announced that the Phase II portion of its adaptive Phase II/III clinical trial...
Takeda’s Zasocitinib Outperforms Deucravacitinib in Psoriasis
STOCKHOLM, Sweden, June 11OSAKA, Japan and CAMBRIDGE, Massachusetts, June 11, 2026, 2026 Takeda has announced positive topline results from...
Advertisements
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
NEW YORK, June 9, 2026 Formation Bio announced the first participant has been dosed in a Phase 1 first-in-human...
Bristol Myers Squibb Secures EU Approval for Sotyktu in Psoriatic Arthritis
PRINCETON, N.J., May 11, 2026 Bristol Myers Squibb announced that the European Commission has approved Sotyktu (deucravacitinib) for the...
Takeda Zasocitinib Shows Strong Phase 3 Psoriasis Data
OSAKA, Japan and CAMBRIDGE, Mass., March 28, 2026 Takeda announced positive results from its Phase 3 LATITUDE clinical trials...
InnoCare Gains NMPA Nod for Phase II TYK2 Lupus Trial
BEIJING, China — December 23, 2025 — InnoCare Pharma has announced a major clinical development milestone with the approval...
Advertisement
